skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines brolucizumabQuestion & answer

brolucizumab · Medicine question

Which receptors does brolucizumab prevent VEGF-A from binding to?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Brolucizumab (Beovu) prevents VEGF-A from binding to its receptors VEGFR-1 and VEGFR-2.

Sources for this answer

Beovu 120 mg/ml solution for injection in pre filled syringeNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 12Document updated 13 May 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

More questions about brolucizumab

Have medicine interaction studies been performed with brolucizumab?How is brolucizumab (Beovu) administered, and which specialist must administer it?How long is effective contraception recommended during and after brolucizumab treatment?How much polysorbate 80 does each Beovu 120 mg/ml brolucizumab pre-filled syringe contain?What are the breastfeeding restrictions during and after brolucizumab treatment?What does the product information say about using brolucizumab during pregnancy?

brolucizumab

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the brolucizumab guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX